News Sep 28, 2025
Porton Shanghai Pudong Facility Obtained ISO 14001 and ISO 45001 Certification
Porton Pharma's Shanghai Pudong site successfully obtained ISO 14001 and ISO 45001 certifications, enhancing sustainable operations and CDMO capabilities for biotech clients.
News Sep 25, 2025
Porton Pharma Makes China's Innovative Pharmaceuticals Decennial Honor Roll, Secures 'Industry-Leading CDMO' Title
Porton Pharma honored as Industry Leading CDMO Company for innovative drug development services. Learn more about our award and global capabilities.
News Sep 24, 2025
Porton Congratulates Partner GenFleet Therapeutics on Its HKEX Main Board Debut
GenFleet Therapeutics listed on HKEX Main Board (2595.HK). Porton, its CDMO partner, highlights API development for Fuzerelase. Learn about the IPO success.
News Sep 07, 2025
2025 DUCHENNE AWARENESS DAY
Join the WeCare Program in celebrating World Duchenne Awareness Day. Support DMD families and promote understanding of Duchenne Muscular Dystrophy.
NewslettersSep 04, 2025
Porton Newsletter - August 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
News Sep 01, 2025
Porton to Showcase Integrated CDMO Expertise at BIOSPAIN 2025
Porton to Showcase Integrated CDMO Expertise at BIOSPAIN 2025
News Aug 29, 2025
Porton's End-to-End CMC Development Accelerates Market Approval for Innovative ALK Inhibitor Dirozalkib (Xuanfeining) Tablets
As the sole CDMO service provider for the active pharmaceutical ingredient (API) of Dirozalkib
News Aug 29, 2025
Porton Supports BioNova's BN104 Program in Achieving Milestone Entry into Overseas Markets
BioNova & Porton Annual Collaboration Review and Award Ceremony
News Aug 22, 2025
PORTON 2025 H1 PERFORMANCE HIGHLIGHTS
PORTON 2025 H1 PERFORMANCE HIGHLIGHTS
